Vertex launches pivotal trial for stem-cell derived islet therapy - Breakthrough T1D
Vertex announced the first stem cell-derived islet therapy is entering a phase 3 clinical trial for type 1 diabetes.| Breakthrough T1D
Vertex announced the first stem cell-derived islet therapy is entering a phase 3 clinical trial for type 1 diabetes.| Breakthrough T1D
The recipient of gene-edited islets to evade the immune system is making insulin without the use of immunusuppresives.| Breakthrough T1D
